Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: A new ALK isoform transported by extracellular vesicles confers drug resistance to melanoma cells

Fig. 3

The combination of ALK and PLX4032 inhibitors is efficient in resistant melanoma cells. (a) ALK inhibitors (Crizotinib, Ceritinib and ASP3026) dose-response in resistant A375X1 cells cultured in the absence or presence of 1 μM of PLX4032. (b) PLX4032 dose-response in resistant cells cultured with or without 1 μM of ALK inhibitors. (c) Western blot analysis of resistant A375X1 cells treated with PLX4032 for the indicated time points in the presence of absence of ALK inhibitors. α-Tubulin was used as a loading control and one representative of three biological replicates is shown. (d) Apoptosis assays showing the activity of caspase-3 in resistant and sensitive cells treated either with single inhibitors or with a combination of ALK and BRAF inhibitors, normalised to the untreated control. Error bars represent the standard deviation of three technical replicates of three biological replicates. Statistical significance was determined with a one-way ANOVA coupled with Tukey’s multiple comparison tests. *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page